Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944785 · ClinicalTrials.gov registry record
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
A clinical trial, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- 164
- Enrollment target
NCT03944785: Completed study, sponsored by Supernus Pharmaceuticals.
NCT03944785 is a clinical trial that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 164 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03944785 has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- 164 participants
- Enrollment target
Study Summary
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
Primary Outcome
MDS-UPDRS: 4-part assessment of the multiple clinical disabilities of Parkinson's Disease. Part I (13 items; Score 0-52) examines non-motor experiences, Part II (13 items; Score 0-52) examines motor experiences, Part III (33 items; Score 0-132) examines the cardinal motor disabilities and Part IV (6 items; Score 0-24) examines motor complications. Each Part has 0-4 ratings, where 0 (no problems) to 4 (severe problems) and scores for each part are summed to calculate the total score which ranges
Interventions
- DRUG XADAGO (safinamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2020-01-10 |
What the finished NCT03944785 record still lists
NCT03944785 is an observational study that tracks outcomes without assigning an intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which XADAGO (safinamide) is the first listed.
NCT03944785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03944785 about?
NCT03944785 is a clinical study titled "Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)". This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
What is the current status of trial NCT03944785?
This trial is currently completed. The enrollment target is 164 participants. The study started on 2017-11-30. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT03944785?
The interventions under investigation include: XADAGO (safinamide) (DRUG).
Who is sponsoring clinical trial NCT03944785?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI